CER-001 Infusions in Subjects with Familial HDL-c Deficiency

Trial Profile

CER-001 Infusions in Subjects with Familial HDL-c Deficiency

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs CER 001 (Primary)
  • Indications Hypoalphalipoproteinaemia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SAMBA
  • Sponsors Cerenis Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Sep 2014 Results published in the Media Release.
    • 02 Jun 2014 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top